ArticleMedical gas research2027
HydroMg attenuates doxorubicin-induced myocardial injury via promoting mitochondrial function.
Article in Medical gas research, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In contrast to molecular hydrogen's intrinsic limitations, HydroMg's structural optimization shortens gastrointestinal transit, reducing hydrogen dissipation while enhancing cellular bioavailability. However, it remains unclear whether it also provides protection against cardiac injury. Here, we investigated the cardioprotective effect of HydroMg, a sustained-release hydrogen donor, against doxorubicin-induced cardiac injury. In vitro studies showed that 1 μg/mL HydroMg treatment attenuated doxorubicin-induced cardiomyocyte death by inhibiting apoptosis, reducing reactive oxygen species production, and restoring mitochondrial membrane potential. The cardioprotective effect of HydroMg (20, 100, 500, and 1000 mg/kg) was further validated in doxorubicin-induced mice. The 100 mg/kg HydroMg group exhibited 35.7% lower mortality than doxorubicin-treated controls. Additionally, HydroMg treatment significantly improved cardiac function and increased left ventricular ejection fraction by 12.44% compared with the doxorubicin-only group. Mechanistically, HydroMg treatment alleviated mitochondrial dysfunction in the doxorubicin-induced cardiotoxicity mouse model by scavenging reactive oxygen species to dually suppress ferroptosis (via solute carrier family 7 member 11/glutathione peroxidase 4 axis upregulation) and apoptosis (characterized by caspase-3 downregulation and Bcl-2 upregulation). Overall, HydroMg treatment inhibits doxorubicin-induced mitochondrial dysfunction by attenuating reactive oxygen species overproduction, thereby suppressing ferroptosis and apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.